Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals
Journal of Antimicrobial Chemotherapy · 03.11.2026 · 81 (12)
DOI: 10.1093/jac/dkag355 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 03.11.2026. Verfasst von Bárbara Pocongo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Nacional de Luta Contra SIDA (INLS), Ministério da Saúde, Luanda, Angola. Hauptthemen laut MEDLINE: HIV-1, HIV Integrase Inhibitors, Drug Resistance, Viral, HIV Infections. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ações para Realização e Promoção da Pesquisa, Desenvolvimento Tecnológico, Inovação e Ensino no IOC, PAEF: Projeto de Ações Estratégicas e de Fortalecimento.
Abstract (Originalsprache)
Background
Africa remains a major epicentre of the global HIV epidemic, with Central Africa exhibiting extensive HIV-1 genetic diversity that may influence the emergence and transmission of drug resistance mutations. Following World Health Organization recommendations, Angola initiated the national transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in 2021. This study evaluated the frequency, patterns and temporal trends of HIV-1 drug resistance mutations before and after DTG implementation (2019–23), while also characterizing HIV-1 genetic diversity across Angolan provinces outside Luanda.
Methods
A retrospective observational analytical study comparing pre- and post-Integrase strand transfer inhibitor (INSTI) introduction periods was conducted using plasma samples and dried blood spot cards from 17 provinces of Angola.
Results
Of the 201 samples analysed, 102 were successfully sequenced for at least one coding region [protease (n = 65); reverse transcriptase (n = 66); integrase (IN) (n = 86)], comprising 48 INSTI-naive people living with HIV and 54 INSTI-experienced people living with HIV samples. Subtype C was the most prevalent (21.6%), followed by unique recombinant forms (20.6%), A1 (15.7%), F1 (13.7%), CRF02_AG (10.8%), G (8.8%) and other subtypes or recombinants (8.8%). Resistance to non-nucleoside reverse transcriptase inhibitors was the most common (68.2%; 95% CI 56.2–78.2), followed by nucleoside reverse transcriptase inhibitors (48.5%; 95% CI 36.8–60.3). Resistance to protease inhibitors (PIs) and INSTIs was lower, observed in 1.5% (95% CI 0.3–8.2) and 3.5% (95% CI 1.2–9.8), respectively.
Conclusions
In this analysis, substantial HIV-1 genetic and epidemiological complexity was observed. In the context of the rapid scale-up of DTG-based ART, continued surveillance of INSTI resistance mutations has become increasingly important to inform evidence-based public health strategies aimed at preventing the transmission of drug-resistant HIV strains and optimizing ART regimens at the population level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto Nacional de Luta Contra SIDA (INLS), Ministério da Saúde, Luanda, Angola.
- Global Health and Tropical Medicine, GHTM, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, Lisboa, Portugal.
- Tufts University School of Medicine, Boston, MA, USA.
- Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Rio de Janeiro 21045-900, Brazil.
- Instituto Adolfo Lutz, Centro de Virologia, São Paulo, SP, Brazil.
- Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Bárbara Pocongo, Seth Inzaule
Förderung
- Ações para Realização e Promoção da Pesquisa
- Desenvolvimento Tecnológico, Inovação e Ensino no IOC
- PAEF: Projeto de Ações Estratégicas e de Fortalecimento
- Estudos imunológicos, virológicos e genômicos em IST/AIDS, HIV, COVID-19 e suas coinfecções
- FTC
- Fundação para Ciência e Tecnologia
- R&D unit Global Health and Tropical Medicine
- Associated Laboratory in Translation and Innovation
Zitieren
APA
Pocongo, B., Furtado, M., Bernardi, C., Jacinto, L., José, A., Urica, J., Torres, R., Vunge, F., Almeida, B., Jordan, M. R., Jesus, C., Guimarães, M. L., Ahagon, C. M., Lopes, G., Brígido, L., Inzaule, S., Abecasis, A. B., Parreira, R., Piedade, J., & Pimentel, V. (2026). Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals. Journal of Antimicrobial Chemotherapy, 81(12). https://doi.org/10.1093/jac/dkag355
Vancouver
Pocongo B, Furtado M, Bernardi C, Jacinto L, José A, Urica J, et al. Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals. Journal of Antimicrobial Chemotherapy. 2026;81(12). doi:10.1093/jac/dkag355
BibTeX
@article{Pocongo2026,
author = {Pocongo, Bárbara and Furtado, Maria and Bernardi, Cláudia and Jacinto, Lucrécia and José, Aulória and Urica, Jaime and Torres, Rosa and Vunge, Francisco and Almeida, Beatriz and Jordan, Michael R and Jesus, Carlos and Guimarães, Monick Lindenmeyer and Ahagon, Cíntia Mayumi and Lopes, Giselle and Brígido, Luís and Inzaule, Seth and Abecasis, Ana B and Parreira, Ricardo and Piedade, João and Pimentel, Victor},
title = {Understanding integrase inhibitor resistance in Angola: a comparative analysis of INSTI-naive and INSTI-experienced individuals},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {12},
doi = {10.1093/jac/dkag355}
}
EUVIMED